Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
Executive Summary
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews
You may also be interested in...
With Streamlined Pipeline, Next Steps For Sanofi R&D Include Full Reorg
Sanofi Aventis has already cut 14 projects from its pipeline since February, but there could be more coming by the end of the year - and with a possible Plavix successor among the compounds in limbo, those decisions will be a true test of whether Sanofi is really going to steer clear of "me-too" type products that may be a tougher commercial climb
With Streamlined Pipeline, Next Steps For Sanofi R&D Include Full Reorg
Sanofi Aventis has already cut 14 projects from its pipeline since February, but there could be more coming by the end of the year - and with a possible Plavix successor among the compounds in limbo, those decisions will be a true test of whether Sanofi is really going to steer clear of "me-too" type products that may be a tougher commercial climb
Sanofi Cuts Development Of 14 Drugs In First Quarter, With More R&D Changes To Come
Among halted development programs is Phase III antidepressant saredutant; decision on Plavix follow-on idrabiotaparinux awaits FDA safety determination.